Abstract
Peroxisome proliferator-activated receptorδ (PPARδ) belongs to the PPARs receptor family including PPARα, PPARδ, and PPARγ. PPARδ is a ligand-activated transcription factor that plays a critical role in regulating cancer progression. PPARδ-linked tumorigenesis was first identified in colorectal cancer, which is demonstrated by the following evidences, so PPARε is a potential drug target for colorectal cancer. In contrast, some observations show that PPARδ negatively regulates colorectal cancer event. In the present review, the recent progress of PPARδ signaling-mediated colorectal cancer is covered.
Keywords: Colorectal cancer, PPARδ, signaling.
Current Pharmaceutical Design
Title:PPARδ Signaling Regulates Colorectal Cancer
Volume: 21 Issue: 21
Author(s): Mengli You, Shuping Yuan, Juanjuan Shi and Yongzhong Hou
Affiliation:
Keywords: Colorectal cancer, PPARδ, signaling.
Abstract: Peroxisome proliferator-activated receptorδ (PPARδ) belongs to the PPARs receptor family including PPARα, PPARδ, and PPARγ. PPARδ is a ligand-activated transcription factor that plays a critical role in regulating cancer progression. PPARδ-linked tumorigenesis was first identified in colorectal cancer, which is demonstrated by the following evidences, so PPARε is a potential drug target for colorectal cancer. In contrast, some observations show that PPARδ negatively regulates colorectal cancer event. In the present review, the recent progress of PPARδ signaling-mediated colorectal cancer is covered.
Export Options
About this article
Cite this article as:
You Mengli, Yuan Shuping, Shi Juanjuan and Hou Yongzhong, PPARδ Signaling Regulates Colorectal Cancer, Current Pharmaceutical Design 2015; 21 (21) . https://dx.doi.org/10.2174/1381612821666150514104035
DOI https://dx.doi.org/10.2174/1381612821666150514104035 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Doxorubicin-Loaded Nanoparticles: New Advances in Breast Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Synthetic Lethality: From Research to Precision Cancer Nanomedicine
Current Cancer Drug Targets Dexamethasone Reduces Cell Adhesion and Migration of T47D Breast Cancer Cell Line
Anti-Cancer Agents in Medicinal Chemistry Dual-target Inhibitors Based on BRD4: Novel Therapeutic Approaches for Cancer
Current Medicinal Chemistry Influence of the Bystander Effect on HSV-tk / GCV Gene Therapy. A Review.
Current Gene Therapy MicroRNA-582-5p Reduces Propofol-induced Apoptosis in Developing Neurons by Targeting ROCK1
Current Neurovascular Research Threes Company: Regulation of Cell Fate by Statins
Current Drug Targets - Cardiovascular & Hematological Disorders Treatment of Estrogen Receptor-Positive Breast Cancer
Current Medicinal Chemistry Hormetic Potential of Sulforaphane (SFN) in Switching Cells’ Fate Towards Survival or Death
Mini-Reviews in Medicinal Chemistry Vitamin Bs, One Carbon Metabolism and Prostate Cancer
Mini-Reviews in Medicinal Chemistry Cancer Stem Cells: How can we Target them?
Current Medicinal Chemistry SPARC in Tumor Pathophysiology and as a Potential Therapeutic Target
Current Pharmaceutical Design Reversal of Resistance to Oxazaphosphorines
Current Cancer Drug Targets Patent Annotations
Recent Patents on Anti-Cancer Drug Discovery Alkaloids as Important Scaffolds in Therapeutic Drugs for the Treatments of Cancer, Tuberculosis, and Smoking Cessation
Current Topics in Medicinal Chemistry Hypomethylation and Activation of Syncytin-1 Gene in Endometriotic Tissue
Current Pharmaceutical Design A Review on Theragnostic Applications of Micrornas and Long Non- Coding RNAs in Colorectal Cancer
Current Topics in Medicinal Chemistry Prostaglandin E2 Receptors as Potential Bone Anabolic Targets – Selective EP4 Receptor Agonists
Current Molecular Pharmacology Polymeric Nanotubes and Nanorods for Biomedical Applications
Current Nanoscience Preface
Current Medicinal Chemistry - Anti-Cancer Agents